Galectin Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GALT Nasdaq 2836 galectintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Galectin Therapeutics Inc.

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology - May 11th, 2026 6:00 am
Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock? - Apr 3rd, 2026 10:00 am
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update - Mar 31st, 2026 6:00 am
Galectin Therapeutics Strengthens Board of Directors with Appointment of Henry Brem, M.D. - Mar 17th, 2026 6:00 am
Galectin Therapeutics Highlights Belapectin Data in MASH Cirrhosis KOL Event, Eyes Next Steps - Mar 16th, 2026 8:34 pm
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension, on March 10, 2026 at 12:00 PM ET - Feb 26th, 2026 2:05 pm
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are retail investors with 55% stake, while 20% is held by insiders - Jan 22nd, 2026 7:18 am
Galectin Therapeutics Receives FDA Written Response on Belapectin, Adds $10 Million Credit Line - Dec 19th, 2025 7:50 am
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027 - Dec 19th, 2025 6:00 am
Galectin Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update - Nov 14th, 2025 6:00 am
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting - Nov 10th, 2025 6:00 am
Galectin Therapeutics to Present at the American Association for the Study of Liver Disease (AASLD) Liver Meeting 2025 - Oct 7th, 2025 6:00 am
Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials - Sep 23rd, 2025 5:21 pm
Galectin Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Sep 2nd, 2025 6:00 am
Galectin Therapeutics Inc.'s (NASDAQ:GALT) top owners are individual investors with 54% stake, while 21% is held by insiders - Aug 15th, 2025 7:38 am
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update - Aug 14th, 2025 6:00 am
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 - Jul 9th, 2025 6:00 am
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension - Jun 10th, 2025 6:56 am
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - May 15th, 2025 6:00 am